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The mortality rate of bacterial meningitis remains high (1), and >50% of patients
who survive are left with significant neurological sequelae (2). A poor outcome is
particularly characteristic of pneumococcal disease, for which the current mortality
rate approaches 30% despite effective antibiotic-induced bacterial killing. Patholog-
ical changes associated with meningeal inflammation include arteritis, thrombophle-
bitis, increased intracranial pressure, brain edema, and altered cerebral blood flow
(3, 4). Since the amount of inflammation in the subarachnoid space correlates with
outcome of disease (5), it is important to understand details of the inflammatory
cascade triggered during meningitisin order to design improved therapy. The subarach-
noid space is sequestered behind the blood brain barrier and has few, if any, resident
host defenses. Thus, the generation ofinflammation at this site necessitates commu-
nication across the blood brain barrier and recruitment of host defenses from blood
to the cerebrospinal fluid (CSF)' space. We sought to define the role of cytokines
in generating inflammation and tissue damage in the subarachnoid space.
Cytokines are thought to mediate many host responses to bacterial infection.
TNF/cachectin and IL-1 play a central role in many responses to infection (6-9),
and antibodies to these cytokines can dramatically improve the course ofinflamma-
tory events in bacterial sepsis (10). However, since the subarachnoid spaceis essentially
an immunocompromised site, the activitiesofcytokines in peripheral infections cannot
be extrapolated to meningitis. Increased circulating cytokine concentrations have
been found inconsistently in states of sepsis (11). Both TNF and IL-1 have been de-
tected in CSF of some patients with meningitis (12, 13), and during Gram-negative
meningitis in a rabbit model (14, 15). The sources of IL-1 and TNF in meningitis
are unknown . Microglial cells in the brain have been shown to produce IL-1 and
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TNF (16), and it is possible that cerebral capillary endothelia may produce such
mediators as has been shown for peripheral vascular endothelium (17).
IL-1 mediates several systemic changes associated with infection, such as fever,
neutrophilia, increased hepatic acute phase protein synthesis, hypoferremia, and
elevated corticosteroid levels (7, 18). IL-1 exerts biological effects on circulating gran-
ulocytes (19) and endothelium (20). IL-1 ahas been shown to increase vascular per-
meability in the rabbit lung (21) and to disrupt the blood brain barrier in the rat (22).
TNF is a cytokine produced by monocytes and macrophages in response to bac-
terial LPS, IL-2, and mitogens (8). The effects of TNF in vivo include induction
of fever (8), induction of IL-1 production by vascular endothelium, and activation
of multiple leukocyte functions (6, 10). The histopathologic damage seen in lungs,
intestine, kidneys, pancreas, and adrenals in TNFtreated animals resembles that
induced by endotoxemia (6).
Wolpe et al. (23, 24) recently characterized two novel cytokines termed "macro-
phage inflammatory protein" (MIP)-1 and -2, both ofwhich exhibit a strong affinity
for heparin. MIP-1 is produced by endotoxin-stimulated macrophages. It is mildly
chemotactic for human neutrophils in vitro and induces them to undergo an oxida-
tive burst. When injected subcutaneously into the foot pads of C3H/HEJ mice (en-
dotoxin resistant), a cellular infiltratecomprised primarily of neutrophils is induced.
In addition, MIP-1 is an endogenous pyrogen that acts in a prostaglandin-independent
manner (25). The other major heparin-binding protein secreted by endotoxin-
stimulated macrophages is MIP-2. Sequence analysis indicates that MIP-2 is a member
of the platelet factor 4 family. This mediator is an extremely potent chemotactic
agent for human neutrophils but induces little chemokinetic activity in vitro. It does
not induce an oxidative burst in parallel assays in which MIP-1 is active. MIP-2
also causes a localized inflammatory reaction when injected into foot pads of mice.
The major pathological feature of acute bacterial meningitis is the presence of
an inflammatory exudate within the subarachnoid space. We explored the role of
TNF, IL-1a, IL-1(3, MIP-1, and MIP-2 in generating this inflammatory response.
Using an experimental model of pneumococcal meningitis in rabbits, the spectrum
ofintracranial abnormalities induced by intracisternal administration ofeach cytokine
was found to be different. Specific antibodies to these mediators reduced inflamma-
tion and tissue damage in pneumococcal meningitis.
Materials and Methods
Bacterial Components, Cytokines, and Antibodies.
￿
Unencapsulated Streptococcus pneumoniae strain
R6 was grown to mid-logarithmic phase, boiled for 20 min in growth medium, washed, and
resuspended in pyrogen-free saline (26). 108 cell equivalents were administered intracister-
nally in a volume of0.2 ml, and a highly reproducible inflammatory response indistinguish-
able from natural disease was generated in CSF over 5 h.
The inflammatory response produced by intracisternal instillation of the following cytokines
was compared with that of S. pneumoniae: recombinant human (rh)TNF-a (2 x 108 U/mg)
(Chiron Corp., Emeryville, CA); rhIL-la (107 U/mg) (Lot SM46; courtesy of Dr. P.
Lomedico, Hoffman-La Roche, Inc., Nutley, NJ); rhIL-1,8 (106 U/mg) (courtesy of Dr. J.
Schmidt; Merck, Sharpe & Dohme Research Laboratories, Rahway, NJ); murine MIP-1 (400
t~g protein/ml) (23); and murine MIP-2 (100,ug protein/ml) (24). Recombinant cytokines
contained <10 pg endotoxin/ml. The endotoxin content of native cytokines was unknown;
to neutralize the possible effects of residual endotoxin in all cytokine preparations, all medi-
atorswere tested with and without addition ofpolymyxin B (50 Wg/kg, intracisternally) (SigmaSAUKKONEN ET AL.
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Chemical Co., St. Louis, MO). All cytokines were >99% pure as assessed by gel electro-
phoresis.
The ability of the following antibodies to neutralize CSF inflammation was tested. Anti-
rh TNFa (raised in goat and crossreactive with rabbits [27])and preimmune goat antiserum
were a gift of Dr. R. Ulevich (Scripps Clinic, La Jolla, CA). Two goat antibodies were ob-
tained from Dr. Richard Chizzonite(Hoffman-La Roche, Inc.): anti-rhIL-la and anti-rhIL-
10 (1.3 mg antibody/ml; batches 162 and 168, respectively). Antisera to MIP-1 and -2 were
produced in rabbits against murine material by one ofus (B. Sherry). Antibodies (200 Al/rabbit)
were administered intracisternally simultaneously with the cytokines. Control rabbits received
antibody alone.
Rabbit Model ofMeningitis.
￿
The rabbit model was performed according to an established
protocol (25, 28, 29). For all experiments, rabbits were challenged in groups of at least four
per cytokine per dose. In brief, 2-kg female, specific pathogen-free, New Zealand white rabbits
(Hare Marland, Nutley, NJ) were anesthetized with ketamine and xylazine, and a dental
acrylic helmet was affixed to the calvarium. 24 h later, the animals were anesthetized with
urethane and phenobarbital and placed in a stereotaxic frame. A spinal needle was intro-
duced into the cisterna magnaand 300 p,l CSF was withdrawn. Heat-killed S pneumoniae R6
(2 x 107/rabbit) or cytokines (TNF, IL-1, MIP-1, MIP-2) were instilled into the subarach-
noid space in a volume of4200 pl pyrogen-free saline. In some experiments, antibodies or
polymyxin B were mixed with the cytokines and administered simultaneously. CSF was with-
drawn at 2-h intervals over 6 h and tested for leukocyte density using a counter (Coulter
Electronics Inc., Hialeah, FL) and differential cytology using DiffQuik stain (American
Scientific Products, Edison, NJ). The CSF samples were centrifuged at 10,000 g for 5 min,
and the supernatant fluidwas frozen at - 70°C until assayed for protein with theBCA method
(Pierce Chemical Co., Rockford, IL). After 6 h, animals were killed with an overdose of
phenobarbital, and brains were removed immediately for quantitation of brain edema by
comparing wet/dry weight (g H2O/100 g dry weight) (30).
To determine if the pathological changes induced by cytokines required participation of
leukocytes, challenge with the cytokines was tested in rabbits treated with intravenous mAb
1134 (1 mg/kg) (obtained from Dr. S. D. Wright, The Rockefeller University) (31, 32). This
antibody binds to the CD18 complex of receptors on leukocytes, thereby preventing adhesion
ofleukocytes to endothelia, a prerequisite to diapedesis (31). The antibody effectively blocks
emigration of leukocytes into the CSF in this model (32).
Statistical Methods.
￿
Values are presented as the means of four or more rabbits/group t
SD. Comparison between means ofgroups ofrabbits was carried out usingthe student's ttest.
Results
InflammatoryActivity ofCytokines.
￿
When instilled into the subarachnoid space, four
of five cytokines induced movement ofleukocytes across the blood brain barrier into
the CSF Simultaneous administration of polymyxin B with the cytokines had no
effect on the magnitude of leukocytosis for any mediator (data not shown). IL-10
had no chemotactic activity, even at a dose of 300 ng/animal, a value 100-fold higher
than the lowest active dose of IL-la. Fig. 1 shows the dose-response curves for
chemotactic activity of four mediators: TNF, IL-la, MIP-1, and MIP-2. IL-la had
the highest specific activity on a per weight basis. However, the onset ofleukocytosis
was most rapid for TNF (1 h) followed by IL-1a (2 h), then MIP-1 (4h), and MIP-2
(4 h). MIP-1 was 100 times more potent than MIP-2. The polymorphonuclear leu-
kocyte was the initial cell type present in all exudates (Table I), a feature also charac-
teristic of natural infection with the pneumococcus. However, in the cases of TNF
and MIP-1, the predominant cell type shifted to mononuclear cells between 4 and
6 h after challenge (Table 1).
When cytokines were mixed with homologous specific antibody and then ad-442
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TNF
2 4 6 a
Hours
TABLE I
Induction of Leukocytosis and Brain Edema by
Intracisternal Instillation of Cytokines
CSF leukoc
FIGURE 1. Dose-response curves for CSF
leukocytosis induced byfour cytokines injected
intracisternally into rabbits. Concentrations
for IL-la and TNF are indicated in U in-
jected/ animal (0.05 U IL-la = 1 pg; 104
U TNF = 100 ng). Concentrations for MIP-1
and MIP-2 are in jig injected/animal.
Minimum dose at which leukocytosis developed in CSF as per Fig. 1 (ng in-
jected: IL-1oa, 0.002 ; IL-1/3, 3; TNF, 50; MIP-1, 1 ; MIP-2, 100).
t P, polymorphonuclear leukocyte; M, mononuclear leukocyte .
PBS diluent for all Cytokine preparations .
II p < 0.01, compared with Cytokine alone.
tosis
Cell types
Brain edema
(H20/100 g dry
weight at 6 h)
g ± SD
397 ± 2
398 ± 3
P 407 ± 5
P 393 ± 611
399±3
398 + 4
P-+M 419+3
- 392 f 511
P-M 412 + 4
- 386 + 711
P 410 f 6
- 393 ± III
Cytokine"/antibody (A) Density
cell/,al ± SD
Control§ 60 + 35
Pooled A 35 f 19
IL-1a 2,343 ± 183
IL-la + A to IL-la 612 + 14411
IL-1/3 35 f 23
IL-1/3 + A to IL-113 58 t 13
TNF-a 1,860 ± 907
TNF-a + A to TNF 46 ± 2911
MIP-1 2,308 t 407
MIP-1 + A to MIP-1 346 f 5211
MIP-2 2,154 f 168
MIP-2 + A to MIP-2 232 t 16511SAUKKONEN ET AL.
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ministered intracisternally, leukocytosis was inhibited in all cases (Table I). This fact,
taken together with thegreatlydiffering purification procedures ofMIN and MIP-2,
suggests that the low bioactivity of MIP-2 was not due to contamination by MIN.
The neutralizing activities ofheterologous anticytokine antibodies were also tested.
The chernotactic effect of IL-la was not greatly influenced by antibodies to other
cytokines (CSF leukocyte densities remained >707o of values for IL-la alone). In
contrast, antibody to IL-la or -(3 decreased leukocytosis due to TNF by >80%, and
antiTNF reduced leukocytosis caused by MIP-1 or MIP-2 by >75%. The onset of
leukocytosis after challenge with IL-1 or TNF was delayed 2 h in animals receiving
anti-MIP-1 and anti-MIP-2.
The Ability of Cytokns to Induce Blood Brain Barrier Injury and Brain Edema.
￿
Two
parameters of brain injury were assessed in cytokine-challenged animals: the ap-
pearance ofserum proteins in CSF (the hallmark ofblood brain barrierbreakdown)
and the development of brain edema. All cytokines caused an increase in protein
concentration in CSF. At 6 h post-challenge, values for each mediator administered
as in Table I were as follows (mg/100 ml): control, 50 t 10; IL-la, 170 t 24; TNF,
117 t 7; MIP-1, 157 t 22; MIP-2, 170 t 36 . The time course of the increase cor-
related with the appearance of leukocytes (as shown in Fig. 1). All cytokines also
caused adramatic increase in brainwatercontent (Table I). Homologous antibodies
to each mediator decreased the protein influx by a maximum of only 48% (data
not shown) but greatly reduced brain edema (Table I).
In rabbits treated with anti-CD18 antibody IB4 (neutrophil adherence dysfunc-
tional), leukocytes failed to accumulate in CSF in response to all cytokines (max-
imum 266 t 23 cells/ttl using protocol of Table I). Under these conditions, the
cytokines also lost the ability to induce brain edema (all brain weights, <399 t 3.7),
but some protein still accumulated in CSF (values for the four cytokines alonewere
all >130 ± 23 mg protein/100 ml CSF at 6 h post-challenge; cytokine intracister-
nally plus IB4 intravenously 90-112 ; IB4 intravenously alone, 81 t 7).
Neutralization of CSF Inflammation Induced by the Pneumococcus by Anticytokine Anti-
bodies. Anticytokine antibodies were administered intracisternally simultaneously
with pneumococci, and the course of inflammation was followed. The onset of leu-
TABLE II
Effect ofAnticytokine Antibodies on CSF Inflammation Induced by Pneumococci
Values are expressed as t SD.
l As per Table 1.
5 P < 0.01.
Challenge inoculum
CSF
Density
leukocytosis'
Onset Peak
Cell
typel
CSF protein
concentration
(at 6 h)
Brain edema
(H20/100 g dry
weight at 6 h)
cells/#l h h mg/10o ml g
Pneumococcus alone 2,975 t 139 4 >6 P 352 t 12 413
+ anti-TNF 399 t 265 4 >6 P-.M 184 t 27.65 388§
+ anti-IL-la + -/3 140 1 0.75 4 4 P 198 1 17.75 410
+ anti-MIP-1 2,885 ± 92 6 >6 P-M 125 t 35.45 412
+ anti-MIP-2 2,842 t 106 6 >6 P 134 t 19.85 410
+ Preimmune serum 1,863 t 142 4 >6 P 327 t 46 412444
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kocytosis usingpneumococci aloneoccurred reproducibly at 4 hand the peak value
of leukocyte densityoccurred at 6 h, rangingfrom 3,500 to 4,000cells/1.1. After treat-
ment with antibodies to TNF or a combination of anti-IL-la and -(3 CSF leukocy-
tosis was almost completely inhibited (Table II). In contrast, anti-MIP-1 and anti-
MIP-2 did not alter the magnitude of leukocytosis after pneumococcal challenge,
but did cause a 2-h delay in the onset of leukocytosis. All antibodies reduced CSF
protein concentrations, but only antiTNF antibody was protective against brain
edema.
Discussion
Cytokines are central mediators of inflammatory events in peripheral infections.
The studies presented here provide strong evidence that these same mediators also
possess a wide range of inflammatory activities in the central nervous system, a site
sequestered behind the specialized vascular endotheliumcomprising theblood brain
barrier. However, activity in the periphery did not predict activity in the central
nervous system, as exemplified by the inability of IL-10 to cause inflammation in
this model. In fact, IL-la and -(3displayed remarkably different inflammatory prop-
erties in the central nervous system. Four of the five cytokines (except IL-1,(3) in-
duced leukocytosis, bloodbrainbarrier permeability, andbrainedema. In experimental
Gram-negative meningitis in rats or rabbits, peak IL-1 and TNF concentrations in
CSFhave been measured to be in the range of 5 ng/ml (14, 15). In this rabbit model,
only rhIL-la (not rhTNF or rhIL-1/3) induced inflammation at this concentration.
Although physiologically relevant concentrations ofTNF alonemay not induce menin-
geal inflammation, IL-1 and TNF have been shown to be highly synergistic in pe-
ripheral inflammation (33), suggesting TNFmay play an important modulatory role
in IL-1-induced pathological changes during meningitis. This is also supported by
the fact that anti-IL-la or -a antibodies decreased leukocytosis induced by TNF.
The majorchemotoxin during meningealinflammation remainsto be determined.
Although chemotactic in this model, IL-1 is not directly chemotactic in vitro. Such
direct activity has recently been ascribed to two recently isolated cytokines, neutro-
phil activating factor (NAF; 34) and monocyte chemoattractant protein 1 (MCP-1;
35). It is possible that the chemotactic activity of IL-la in this model results from
the ability ofIL-1a to induce production ofeither NAF or MCP-1 in vivo. The ability
of MIP-2 to induce neutrophil chemotoxns in this model suggests that MIP-2 and
the highly homologous protein NAF (34) may have similar biological activities in
vivo. Only TNF and MIP-1 were capableof inducing migrationof monocytes across
theblood brainbarrier. This is consistent with therecent findingthat MIP-1 is related
in peptidesequence to MCP-1, which is monocyte specific (35). The shift in leukocy-
tosis from one cell type to another may relate to the timing of induction of such
cell-specific chemoattractant proteins. This is of relevance in vivo, since the appear-
ance of mononuclear cells heralds the resolution of natural pneumococcal menin-
gitis, raising thepossibility that this bioactivity might benefit the outcome ofdisease.
Each cytokine was demonstrated to invoke a unique constellation of pathological
findings, underscoring the fact that induction of brain damage in meningitis is the
summation of multiple, distinct inflammatory mechanisms. However, determina-
tion of the precise roles ofand relationships amongcytokinesin thecascade ofinflam-
mation in meningitis awaits purification of all these mediators from one species(i.e.,therabbit forthis model), since species-specific differences in activities exist. In fact,
it has been reported that rabbit IL-1/3 has some inflammatory activity in this model
(36), but less than human IL-la. Our data would suggest that determination of the
activity of rabbit IL-la will be important.
The hallmark of blood brain barrier injury is the influx of protein from serum
into CSR Such injury was profound in the cases of IL-lcx, MIP-1, and MIP-2, but
not IL-1 sor TNF. IL-1 /3 reportedly induces vascular permeability in therabbit lung
(21) and ratbrain(22), suggesting that site- and species-specific effects for this cytokine
must be considered. The fact that antibodies to each cytokine did not completely
reverse blood brain barrier permeability may indicate that blood brain barrier in-
jury may originate on the vascular side of the blood brain barrier, a site available
to thecytokines but notthe antibodies, as administered in this model. Alternatively,
cytokines have multiple bioactivities that become apparent at different concentra-
tions and that may lack crossreactivity to neutralizing antibody in vivo. All medi-
atorsdemonstrated the ability to induce brain edema. This effect waslost in animals
with neutrophil adhesive dysfunction, indicating that thechemotactic activity of the
cytokinesrather than a direct effect ofcytokineswas responsible forgenerating brain
edema.
Antibodies to TNF or acombinationofIL-1 a and -a greatly decreasedmeningeal
inflammation dueto pneumococci. In vitro, pneumococci directly stimulateperiph-
eral blood monocytes to produce IL-1x and -/3, but TNF is not produced under
the same test circumstances (37). Thus, it is reasonable to suggest that in natural
infection, pneumococci may directly stimulate production of IL-1ct and -/3, which
may in turn lead to the production of TNF, which synergistically enhances inflam-
mation. Neutralization of MIP-1 and MIP-2 delayed the onset of leukocytosis in
response to pneumococci, suggesting a secondary or modulating role for these
cytokines. Thus, in addition to their known effects in the periphery, cytokines are
active during natural infectionin thecentral nervoussystem. These resultsalso define
important roles for cytokinesin Gram-positive, as well as Gram-negative, infections.
Summary
Cytokines mediate many host responses to bacterial infections. We determined
the inflammatory activities of five cytokines in the central nervous system: TNFa,
IL-Ix, IL-1/3, macrophage inflammatory protein 1 (MIP-1), and macrophage inflam-
matory protein 2 (MIP-2). Using a rabbit model of meningeal inflammation, each
cytokine (except IL-1/3) induced enhanced blood brain barrierpermeability, leukocy-
tosis in cerebrospinal fluid, and brainedema. Homologous antibodies to each medi-
ator inhibited leukocytosis and brain edema, and moderately decreasedblood brain
barrierpermeability. In rabbits treated with anti-CD-18 antibody to render neutro-
phils dysfunctional for adhesion, each cytokine studied lost the ability to cause leu-
kocytosis and brain edema. After intracisternal challenge with pneumococci, anti-
bodies to TNF or IL-1 prevented inflammation, while anti-MIP-1 or anti-MIP-2
caused only a 2-h delay in the onset of inflammation. We suggest these cytokines
have multiple inflammatory activities in the central nervous system and contribute
to tissue damage during pneumococcal meningitis.
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